Yeast-based vaccine for inducing an immune response

Details Yeast-based vaccine for inducing an immune response Yeast-based vaccine for inducing an immune response

2007-02-02

2010-06-15

Nolan, Patrick J. (Department: 1648)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Fungus

C424S184100, C424S192100, C424S204100, C424S206100, C424S209100, C424S195160, C435S069900

Reexamination Certificate

active

07736642

ABSTRACT:
The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of vaccine compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions.

REFERENCES:
patent: 5691189 (1997-11-01), Kurtz et al.
patent: 5830463 (1998-11-01), Duke et al.
patent: 7083787 (2006-08-01), Duke et al.
patent: 7563447 (2009-07-01), Franzusoff et al.
patent: 2003/0008000 (2003-01-01), Wong et al.
patent: 2003/0129197 (2003-07-01), Fiers et al.
patent: 2003/0202982 (2003-10-01), Birkett
patent: 2004/0146976 (2004-07-01), Wittrup et al.
patent: 2004/0156858 (2004-08-01), Franzusoff et al.
patent: 2006/0083718 (2006-04-01), Ginns et al.
patent: 2006/0110755 (2006-05-01), Duke et al.
patent: WO 95/18861 (1995-07-01), None
patent: WO 96/14876 (1996-05-01), None
patent: WO 02/39951 (2002-05-01), None
patent: WO 2004/058157 (2004-07-01), None
patent: WO 2005/116270 (2005-12-01), None
Girard et al., A review of vaccine research and development: The human immunodeficiency virus (HIV), 2006, Vaccine, vol. 24, pp. 4062-4081.
Meyer et al., Antibody-Dependent Enhancement of Hepatitis C Virus Infection, 2008, Journal of Virology, vol. 82, No. 5, pp. 2140-2149.
Kitikoon et al., The antibody responses to swine influenza virus (SIV) recombinant matrix 1 (rM1), matrix 2 (M2), and hemagglutinin (HA) proteins in pigs with different SIV exposure, 2008, Veterinary Microbiology, vol. 126, pp. 51-62.
Cho et al., A yeast surface display system for the discovery of ligands that trigger cell activation, 1998, Journal of Immunological Methods, vol. 220, pp. 179-188.
Gillian, Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus, 1981, PNAS, vol. 78, No. 12, pp. 7639-7643.
Genbank Accession AAW80717, published Feb. 9, 2005.
Genbank Accession CAA96733, published Aug. 11, 1997.
Genbank Accession MFIV, published Jul. 16, 1999.
De Filette et al., Universal influenza A vaccine: Optimization of M2-based constructs, 2005, Virology, vol. 337, pp. 149-161.
Ward et al., Expression and analysis of the NS2 protein of influenza A virus, 1995, Archives of Virology, vol. 140, pp. 2067-2073.
Ilyinskii et al., Inhibition of Influenza M2-Induced Cell Death Alleviates Its Negative Contribution to Vaccination Efficiency, 2008, PLoS ONE, vol. 3, No. 1, pp. 1-4.
A. Haller. “Targeting Influenza with Yeast-Based Immunotherapy”. Keystone Symposia: Advances in Influenza Research: From Birds to Bench to Bedside. Poster Presentation, Mar. 29, 2006, Steamboat CO.
Andreansky et al., “Consequences of Immunodominant Epitope Deletion for Minor Influenza Virus-Specific CD8 +−T-Cell Responses”, Journal of Virology, Apr. 2005, p. 4329-4339.
Epstein et al., “Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein”, Vaccine 23 (2005), pp. 5404-5410.
Ernst et al., “Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines”, Vaccine 24 (2006), pp. 5158-5168.
Fan et al., “Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys”, Vaccine 22 (2004), pp. 2993-3003.
Filette et al., “The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA 1-DD provides complete protection”, Vaccine 2005, 8 pages.
G. Everson. “Interim Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Subjects with Chronic HCV After Treatment with GI-5005, a Yeast-based HCV Immunotherapy Targeting NS3 and Core Proteins.” American Association for the Study of Liver Disease (AASLD) 2006. Poster Presentation, Oct. 30, 2006, Boston MA.
Gao et al., “Protection of Mice and Poultry from Lethal H5N1 Avian Influenza Virus through Adenovirus-Based Immunization”, Journal of Virology, Feb. 2006, p. 1959-1964.
Hoelscher et al., “Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice”, Lancet 2006, vol. 367, pp. 475-481.
Kreijtz et al., “Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubypic virus strain in mice”, Vaccine 2006, 9 pages.
Lu et al., “Mutation-Selective Tumor Remission with Ras-Targeted, Whole Yeast-Based Immunotherapy”, Cancer Research 64, Aug. 1, 2004, pp. 5084-5088.
Mischo et al., “Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients”, Cancer Immunity, vol. 3, Jun. 27, 2003, available at http://ww.cancerimmunity.org/v3p5/030605.htm, 11 pages.
Mozdzanowska et al., “Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2”, Vaccine 21 (2003), pp. 2616-2626.
Plotnicky et al., “The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/Kb transgenic mice”, Virology 309 (2003), pp. 320-329.
Saelens et al., “Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin”, Eur. J. Biochem., vol. 260, 1999, pp. 166-175.
Saiki et al., “Induction of humoral responses specific for paraneoplastic cerebellar degeneration-associated antigen by whole recombinant yeast immunization”, Journal of Autoimmunity 24 (2005), pp. 203-208.
Sato et al., “Long anchor using Flo1 protein enhances reactivity of cell surface-displayed glucoamylase to polymer substrates”, Appl Microbiol Biotechnol (2002) 60, pp. 469-474.
Schreuder et al., “Immobilizing proteins on the surface of yeast cells”, Tibtech, Apr. 1996, vol. 14, pp. 115-120.
Shin et al., “A predictive model for the level of slgA based on IgG levels following the oral administration of antigens expressed inSacchromyces cerevisiae”, J. Vet. Sci, (2005), 6(4), pp. 305-309.
Stubbs et al., “Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity”, Nature Medicine, vol. 7, No. 5, May 2001, pp. 1-5.
Thomas et al., “Cell-mediated Protection in Influenza Infection”, Emerging Infection Diseases, vol. 12, No. 1, Jan. 2006, pp. 48-54.
Townsend et al., “The Influenza A Virus Nucleoprotein Gene Controls the Induction of Both Subtype Specific and Cross-Reactive Cytotoxic T Cells”, J. Exp. Med., vol. 160, Aug. 1984, pp. 552-563.
Treanor et al., “Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine”, The New England Journal of Medicine, vol. 354, No. 13, pp. 1343-1351, 2006.
Van Der Vaart et al., “Comparison of Cell Wall Proteins ofSaccharomyces cerevisiaeas Anchors for Cell Surface Expression of Heterologous Proteins”, Applied and Environmental Microbiology, Feb. 1997, p. 615-620.
Wadle et al., “Cross-presentation of HLA class I epitopes from influenza matrix protein produced inSaccharomyces cerevisiae”, Vaccine 24 (2006), pp. 6272-6281.
Webster et al., “Matrix Protein from Influenza A Virus and Its Role in Cross-Protection in Mice”, Infection and Immunity, Sep. 1977, pp. 561-566.
Schreuder MP, Brekelmans S, van den Ende H, Klis FM. 1993. Targeting of a heterologous protein to the cell wall ofSaccharomy

Affiliated with

Also associated with

Rating

Yeast-based vaccine for inducing an immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Yeast-based vaccine for inducing an immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Yeast-based vaccine for inducing an immune response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4226602